Verrica Pharmaceuticals Inc. (VRCA) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $3.42 (-1.72% 1D, market cap $58.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, VRCA ranks #445 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRCA carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XBIT (XBiotech Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $59.1M) and RFL (Rafael Holdings Inc. (Class B)) posts a E grade (16/100 RQD, P/E N/A, ROIC -35.0%, cap $58.2M). Among the 5-stock peer group, VRCA leads on earnings multiple (N/A) while VRCA leads on capital efficiency (-35.0% ROIC).
Per VRCA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001660334), Verrica Pharmaceuticals Inc. generated $35.6M in revenue (+370.2% YoY), -$17.9M in net income, and -$17.6M in free cash flow against $47.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 34.1 (NEUTRAL RANGE)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While VRCA currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.41) and Max Pain ($3.59) forces dealer call-delta covering toward $10.31.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Verrica Pharmaceuticals Inc. (VRCA) slipped -1.72% to $3.42, trading at 3% of its 52-week range ($3.25 – $9.82). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
– Company’s achievement of pre-defined revenue, growth and operational milestones increases facility commitment by $15.0 million – – Capital now available to support continued growth of the YCANTH® business and advanceme
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on VRCA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for VRCA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Verrica Pharmaceuticals Inc. (VRCA) ranks #445 by composite RQD confidence (44/100, grade D) and #726 by equity capitalization ($58.8M). Within this direct 5-issuer industry benchmark cohort, VRCA leads on earnings valuation at N/A trailing P/E, while VRCA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APLM currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with VRCA at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VRCA
ACTIVE
Verrica Pharmaceuticals Inc. | D | 44/100 | — | — | -35.0% | -1.72% | $58.8M | Benchmark Subject |
| XBIT XBiotech Inc. | D- | 37/100 | — | — | -35.0% | -2.51% | $59.1M | /xbit-vs-vrca → |
| RFL Rafael Holdings Inc. (Class B) | E | 16/100 | — | — | -35.0% | -7.44% | $58.2M | /rfl-vs-vrca → |
| BOLD Boundless Bio Inc. | D- | 41/100 | — | — | -35.0% | -0.80% | $57.3M | /bold-vs-vrca → |
| APLM Apollomics Inc. (Class A) | C | 62/100 | — | — | — | +4.16% | $60.2M | /aplm-vs-vrca → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Verrica Pharmaceuticals Inc. (VRCA) reported GAAP revenue of $35.6M (+370.2% vs. FY2024 revenue of $7.6M , and +594.3% cumulative change since FY2023) , GAAP net income of -$17.9M, operating cash flow of -$17.6M, and free cash flow of -$17.6M (+71.1% YoY). On the balance sheet, VRCA closed FY2025 with $47.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $35.6M | -$17.9M | -$17.6M | -$17.6M | $47.1M | — |
| FY2024 (FY) | 2024-12-31 | $7.6M | -$76.6M | -$60.9M | -$61.0M | $54.1M | — |
| FY2023 (FY) | 2023-12-31 | $5.1M | -$67.0M | -$38.6M | -$38.6M | — | — |
As of 2026-11-02, Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $3.42 (-1.72% 1D, market cap $58.8M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, VRCA ranks #445 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRCA carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XBIT (XBiotech Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $59.1M) and RFL (Rafael Holdings Inc. (Class B)) posts a E grade (16/100 RQD, P/E N/A, ROIC -35.0%, cap $58.2M). Among the 5-stock peer group, VRCA leads on earnings multiple (N/A) while VRCA leads on capital efficiency (-35.0% ROIC).
Per VRCA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001660334), Verrica Pharmaceuticals Inc. generated $35.6M in revenue (+370.2% YoY), -$17.9M in net income, and -$17.6M in free cash flow against $47.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
VRCA last traded at $3.42 (-1.72% on volume of 29,724 shares), positioning the stock -22.45% below its 50-day simple moving average ($4.41) and -39.04% below its 200-day simple moving average ($5.61). Across its 52-week range of $3.25 to $9.82, VRCA sits at the 2.6% percentile with a 14-day RSI of 34.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.99 to $3.85).
Why VRCA Stock slipped -1.72% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).